Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant
form of heart failure worldwide, in tandem with ageing of the general population and the …

There is an unmet need for effective treatment strategies to reduce morbidity and mortality in
patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in …

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …

Background Chronotropic incompetence has shown to be associated with a decrease in
exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet β-blockers are …

Importance Diastolic heart failure (ie, heart failure with preserved ejection fraction) is a
common condition without established therapy, and aldosterone stimulation may contribute …

The clinical syndrome comprising heart failure (HF) symptoms but with a left ventricular
ejection fraction (EF) that is not diminished, eg, HF with preserved EF, is increasingly the …

Aims To determine tolerability and the optimal dose regimen of the soluble guanylate
cyclase stimulator vericiguat in patients with chronic heart failure and preserved ejection …

Key Clinical Points Heart Failure with Preserved Ejection Fraction In patients who have
signs and symptoms of heart failure but a preserved ejection fraction, objective evidence of …

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is
projected to worsen. To date, there are no approved therapies available for reducing …

Hypertension constitutes a major risk factor for heart failure with preserved ejection fraction
(HFpEF). HFpEF is a prevalent clinical syndrome with increased cardiovascular morbidity …